(MedPage Today) — The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on Friday.
The once-daily, fixed…
Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/119017
Author :
Publish date : 2025-12-15 19:12:00
Copyright for syndicated content belongs to the linked Source.
